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The wide life expectancy gap between the old and new member states of the European
Union is most strongly related to the high rate of premature mortality caused by
cardiovascular diseases (CVDs). To learn more about the background of this gap,
the relationship of socioeconomic status (SES) with CVD mortality, morbidity and
the utilization of antihypertensive drugs was studied in Hungary, a Central-Eastern
European country with an extremely high relative risk of premature CVD mortality. Risk
analysis capabilities were used to estimate the relationships between SES, which was
characterized by tertiles of a multidimensional composite indicator (the deprivation index)
and CVD burden (mortality and morbidity) as well as the antihypertensive medications
at the district level in Hungary. The excess risks caused by premature mortality from
CVDs showed a strong correlation with deprivation using the Rapid Inquiry Facility. The
distribution of prevalence values related to these diseases was found to be similar, but
in the areas of highest deprivation, where the prevalence of chronic ischaemic heart
diseases and cerebrovascular diseases was found to be higher than the national average
by 30 and 20%, the prevalence of hypertension exceeded the national average by only
4%. A linear association between the relative frequency of prescriptions/redemptions and
deprivation for most antihypertensive drugs, except angiotensinogen receptor blockers,
was shown. More intense screening for hypertension is proposed to improve the control
of CVDs in countries affected by high disease burden.
Keywords: antihypertensive drugs, cardiovascular mortality, deprivation, primary care, primary non-compliance,
prescription, redemption
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INTRODUCTION
The Marmot’s report (European Commission, 2013) and the
latest joint publication of the OECD and the European
Commission (OECD and EU, 2016) on health and access to
health services demonstrate that significant health inequalities
exist between and within EU member states. The health status
of the populations of the member states that joined the European
Union in 2004 and after (EU13 countries) is less favorable than
that of the countries that became members before 2004 (EU15
countries). Regarding particular causes of death, the largest
contributor to mortality differences is cardiovascular diseases.
Although themortality caused by cardiovascular diseases (CVDs)
is continuously decreasing, the relative risk of premature death,
i.e., the ratio between the early death rates for EU13 countries
compared with that of EU15 countries, is highly unfavorable.
According to the latest available data, the average relative risk
of premature death caused by CVDs is 2.86 in the EU13
countries, and it is particularly high in Bulgaria (4.86), Latvia
(4.69), Lithuania (4.29), Romania (3.53), and Hungary (3.35)
[(World Health Organization (WHO) HFA, 2016)]. Although
these figures clearly indicate that the effectiveness of preventive
interventions against CVDs is not sufficient in these countries,
studies to identify potential targets for prevention measures are
missing.
It is generally accepted that in addition to lifestyle-
modifying interventions, considerable benefit can be derived
from preventive medication. Since hypertension is one of the
most robust predictors of CVD risk (Rapsomaniki et al., 2014)
antihypertensive treatment for blood pressure reduction is
particularly important. Recently it was clearly showed by Vrijens
et al. in a paper based on the outcomes of discussions by a
European group of experts on the current situation of medication
adherence in hypertension that “achieving satisfactory adherence
may have far greater impact than any other maneuver to improve
antihypertensive treatments, and healthcare systems must evolve
to meet this challenge” (Vrijens et al., 2017).
The prevalence of hypertension in different societal groups
has been extensively studied (Li et al., 2017), but the relationship
between SES and hypertension has been reported with conflicting
results. Based on the findings of a systematic search performed
in PubMed, ProQuest and Cochrane databases for observational
studies on hypertension prevalence and SES, a meta-analysis was
carried out. The authors reported an overall increased risk of
hypertension among the lowest SES for income, occupation and
especially for education (Leng et al., 2015).
The results from studies on the relationship between SES
and antihypertensive medication can be interpreted with severe
restrictions. The systematic review and meta-analysis on SES and
non-adherence to antihypertensive drugs showed (Alsabbagh
et al., 2014) that among the 32 studies, only seven examinedmore
than one component while none performed a multidimensional
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor
blocker; CESEE, Central, Eastern and Southeastern Europe; CVD, cardiovascular
disease; DI, deprivation index; RIF, Rapid Inquiry Facility and SES, socioeconomic
status.
assessment. The pooled adjusted risk estimate for nonadherence
according to SES (high vs. low) was 0.89 (0.87–0.92 95%
confidence; P < 0.001). However, the authors concluded that
the individual studies involved in the meta-analysis have not
found a strong association between low SES and nonadherence to
antihypertensive medications. The authors note that important
limitations in the assessment of SES can be identified in virtually
all of the studies and emphasize that “future studies are required
to ascertain whether a stronger association is observed when SES
is determined by comprehensive measures.”
The aim of our present study was to provide data on
cardiovascular disease mortality and morbidity as well as types
of and adherence (primary non-compliance) to antihypertensive
medication in association with the socioeconomic characteristics
of various population groups in Hungary. SES was characterized
by a multidimensional deprivation index as a composite
indicator, which included seven key factors that affect
socioeconomic status. Using a conceptually new approach, the
relationship between prescription and redemption rates was used
to define the contribution of patient and/or physician and/or
health system factors to the inefficiency of antihypertensive
utilization, if one exists, on CVD prevention. Because physicians
in general practice are the key persons that initiate, coordinate,
and provide long-term follow-up for CVD prevention (Mauskop
and Borden, 2011), our study was performed as a cross-sectional
analysis, utilizing data on antihypertensive prescription and
redemption rates from all general practices in Hungary.
MATERIALS AND METHODS
This study focused on the comparative analysis of data
regarding prescriptions by general practitioners and redeemed
prescriptions for antihypertensive drugs in Hungary during
2012, the last year for which all data that are necessary
for a district level analysis were available in the validated
databases. The associations of deprivation with the morbidity
and mortality caused by diseases of the circulatory system
(ICD-10: I00-I99), ischaemic heart diseases (ICD-10: I20-I25),
cerebrovascular diseases (ICD-10: I60-I69), and particularly
hypertensive diseases (ICD-10: I10-I15) as well as the associations
between deprivation and antihypertensive drug utilization
(prescription and redemption) were assessed. The relationship
between the level of deprivation and the prescribing pattern of
antihypertensive drugs was also examined.
Data
For the year 2012, mortality data were derived from the
Hungarian Central Statistical Office, while population data
were obtained from the Central Office for Administrative and
Electronic Public Services. Both mortality and population data
for the districts were stratified by 5-year age bands and sex.
Prevalence data were extracted from the database of the National
Data Collection Programme (report on the activities of general
practitioners and general pediatricians) of the Hungarian Central
Statistical Office for the years 2011–2013 by 10-year age bands. In
our study, data for the 35–64 age group were used.
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The number of prescriptions of antihypertensive drugs
and the number of redeemed antihypertensive prescriptions
were attained for each primary health care practice for the
entire year of 2012 from the National Health Insurance
Fund Administration of Hungary. According to Hungarian
regulations, general practitioners can prescribe only one type
of medicine as a 1-month dose of one prescription for
people who are taking long-term medications. Data on the
prescribed and redeemed antihypertensive drugs were grouped
by commonly used classes, such as diuretics, beta blocking
agents, calcium channel blockers, angiotensin converting enzyme
(ACE) inhibitors, angiotensin receptor blockers (ARBs) and ACE
inhibitors as well as ARBs combined with diuretics (Gu et al.,
2012).
Deprivation Index (DI) Calculation
A deprivation index (DI) was used to provide information about
socioeconomic deprivation compared with the national average
for 2011. Socioeconomic indicators for the DI at the municipality
level were chosen from available data stored at the Regional
Informational System of the Ministry of Local Government
and Regional Development. The data were originally obtained
from Hungarian Central Statistical Office (Census, 2011) and
Hungarian Tax and Financial Control Administration (2011).
The method for calculating DI values and their usefulness
in identifying SES-related inequalities in CVD mortality were
described previously (Juhász et al., 2010), and it was successfully
used in previous studies designed to characterize the association
between deprivation and mortality amenable to healthcare (Nagy
et al., 2012), between deprivation and premature mortality
due to alcoholic liver disease (Nagy et al., 2014) and between
deprivation and statin utilization in Hungary (Boruzs et al.,
2016). Briefly, the DI is based on seven municipality-level
elementary socioeconomic indicators, including income, level of
education, rate of unemployment, rate of one-parent families,
rate of large families, density of housing and car ownership. The
variables were transformed using natural log transformation and
standardization (z-scores). The municipality-specific index is a
weighted sum of the z-scores, with higher values representing
greater deprivation. The weight of each variable was determined
based on the standardized scoring coefficients using a principal
component analysis. The areas with positive index values are
municipalities with a lower socioeconomic status compared with
the national average, and the converse was shown in districts with
negative index values.
Study at the District Level
Administratively, Hungary is divided into 19 counties and the
capital, Budapest; thus, it has 20 European regions at the third
level of the Nomenclature of Territorial Units for Statistics.
The counties are further subdivided into 198 districts, which
constitute the Local Administrative Units 1 that were formerly
known as the Nomenclature of Territorial Units for Statistics
level 4 of Hungary (European Commission, 2007).
In Hungary, the number of GP practices operating in
1 781 municipalities was 6,658 in 2012. The size of the
practices, such as the number of clients served, varied widely
(800–3,000 persons/practice), and the average size was 1,488
persons/practice. Generally, more family practices operate in
higher populated municipalities, whereas one family practitioner
serves more than one municipality in less populated areas.
In addition, there are primary healthcare practitioners with
obligations to provide in-area care and those without such
obligations. Considering the fact that the free choice of family
physicians is a norm in Hungary, that the detailed population
data for practices as well as the antihypertensive utilization data
by age groups are not available due to personal privacy, and that
the DI is not available at the practice level to reduce the risk of
misclassification, we aggregated all data for the district level. The
deprivation for each district was calculated using the population-
weighted average of DI. To define the frequency of prescription
and that of redemption, the denominator was the size of the
>30-year-old population adjusted by the rate of the >60-year-
old population of the district. All districts included in the analysis
were classified into 3 groups or tertiles, ranging from the least
deprived (tertile I) to the most deprived (tertile III), with each
containing a third of the districts analyzed. Grouping the districts
into three tertiles could guarantee the robustness of our results
even in the case when the sample size is relatively low (number of
death caused by hypertensive diseases).
Using the “disease mapping” option within the Rapid
Inquiry Facility (RIF) (Beale et al., 2010), spatial patterns of
cardiovascular mortality (ICD-10: I00-I99) for the 30–64 age
group in 2012 were investigated and visualized at the district
level. Hierarchical Bayesian-smoothed indirectly standardized
mortality ratios (relative risks) were calculated using Besag, York
and Mollie’s model with the INLA method (Besag et al., 1991;
Rue et al., 2009) with the expected cases based on the age-specific
death rates for the Hungarian population. The maps for each
health outcome show the relative risks and exceedance posterior
probabilities (Richardson et al., 2004).
The relative frequency of prescription for the selected drugs
was also mapped for the >30-year-old population using RIF.
The associations among premature mortalities, prevalence of
diseases and the frequency of antihypertensive prescriptions
by agents as well as redeemed antihypertensive prescriptions
by agents were defined using tertiles of DI as a district-based
categorical covariate and the “risk analysis” capabilities of the
RIF. Chi-square tests for homogeneity and linear trend were also
performed to test the global associations of DI with morbidity,
mortality and antihypertensive utilization.
The ratios between the number of redeemed prescriptions and
that of the prescriptions for antihypertensive drugs were used
to characterize the level of primary non-compliance. The results
were analyzed by types of drugs and deprivation tertiles.
RESULTS
The Spatial Distribution of Premature
Mortality and the Prevalence of Selected
Cardiovascular Diseases as Well as Their
Association With Deprivation
Deprivation index values defined by districts varied widely from
−3.76 to +5.83, which indicates a high level of socioeconomic
inequalities in the country. The tertiles based on the DI values
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were defined as ranges of −3.76 ≤ DI ≤ −0.6 with an average
of −1.32 (tertile I); −0.6 < DI ≤ 0.58 with an average of −0.04
(tertile II); and 0.58 < DI ≤ 5.83 with an average of 1.59.
The distribution of the DI values shows that the least-favored
districts were found in the northeastern and southwestern part of
Hungary in 2011. The least deprived districts of the country were
localized at the northwestern region of Hungary, in the capital
city of Budapest and its neighboring areas (Figure 1A). The
FIGURE 1 | The spatial distribution of deprivation (A) and premature mortality due to diseases of the circulatory system in the 30–64 age group (B), and that of
relative frequencies of prescription for ACE inhibitors (C) and ARBs (D) in the >30 age group at district level in 2012 in Hungary.
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spatial distribution of premature mortality due to diseases of the
circulatory system in Hungary was characterized by significant
inequalities, the areas of highest SMRs were found in the eastern
part of the country, and along the north-eastern border of
Hungary (Figure 1B).
The resultant pattern of excess risks caused by the examined
causes of premature mortality showed a correlation with
the spatial pattern of deprivation. The results of the risk
analysis showed a significant association between the risk
of premature cardiovascular mortality and deprivation (χ2
homogeneity = 229.21, P = 0, χ2 linearity = 226.91,
P = 0); between the risk of cerebrovascular premature mortality
and deprivation (χ2 homogeneity = 33.38, P = 0, χ2
linearity = 33.12, P = 0); between the risk of chronic ischaemic
heart diseases and deprivation (χ2 homogeneity = 191.1 P = 0,
χ
2 linearity = 182.58, P = 0); and between the risk of
hypertensive diseases and deprivation (χ2 homogeneity = 23.8
P = 0, χ2 linearity = 23.7, P = 0). Premature mortality
in the areas of the highest deprivation tertile exceeded the
national average mortality by 25% for mortality due to diseases
of the circulatory system, by 22% for mortality due to
cerebrovascular disease, and by 28%—with a wider confidence
interval - for mortality due to hypertensive diseases (Table 1,
Figure 2).
Regarding the relative prevalence values, the results of the risk
analysis also showed a significant association between the relative
prevalence of chronic ischaemic heart diseases and deprivation
(χ2 homogeneity = 41872.22, P = 0, χ2 linearity = 41072.6,
P = 0); between the relative prevalence of cerebrovascular
diseases and deprivation (χ2 homogeneity = 8823.8, P = 0, χ2
TABLE 1 | Relative risks of premature mortality due to diseases of the circulatory system, chronic ischaemic heart diseases, cerebrovascular diseases and hypertensive
diseases for 30–64 age group at the district level in Hungary in 2012 by DI tertiles.
DI tertiles Mortality due to diseases
of the circulatory system
(ICD-10.: I00-I99)
Mortality due to chronic
ischaemic heart diseases
(ICD-10.: I20-I25)
Mortality due to
cerebrovascular diseases
(ICD-10.: I60-I69)
Mortality due to
hypertensive diseases
(ICD-10.: I10-I15)
Relative risk (95% CI) Relative risk (95% CI) Relative risk (95% CI) Relative risk (95% CI)
I. (least deprived) 0.841 [0.812–0.872] 0.817 [0.776–0.859] 0.860 [0.794–0.933] 0.809 [0.711–0.922]
II. 1.004 [0.972–1.037] 0.977 [0.933–1.022] 1.006 [0.934–1.083] 1.017 [0.906–1.142]
III. (most deprived) 1.250 [1.204–1.297] 1.334 [1.269–1.403] 1.217 [1.117–1.327] 1.280 [1.122–1.461]
FIGURE 2 | Relationship between the deprivation and the relative risk of premature mortalities caused by diseases of the circulatory system (A) chronic ischaemic
heart diseases (B), cerebrovascular diseases (C), and hypertensive diseases (D) in 2012 in Hungary.
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linearity= 8241.2, P= 0); and between the relative prevalence of
hypertensive diseases and deprivation (χ2 homogeneity= 7085.9
P = 0, χ2 linearity = 5755.9, P = 0) (Figures 3A–C).
For hypertensive diseases, fewer differences were found in
morbidity associated with deprivation. In the areas of the highest
deprivation tertile, morbidity exceeded the national average by
only 4% (Table 2, Figure 3).
Antihypertensive Drug Utilization
(Prescription and Redemption Rates)
In Hungary, altogether, 41,221,460 antihypertensive regimens
were prescribed in 2012, and only 64.85% of those (26,732,297)
were redeemed. The frequency of prescription was 6.111 [6.108–
6.112] and the frequency of redemption was 3.963 [3.961–3.964]
per person aged >30- year-old (Table 3).
The redemption rate of different types of antihypertensive
drugs differed significantly. The redemption rates of beta
blocking agents, ACE inhibitors, calcium channel blockers,
diuretics, and ARBs were approximately 70%, while the
redemption rates of ACE inhibitors and ARBs combined
with diuretics were significantly lower (46.46 and 36.43%,
respectively). Furthermore, the lowest frequencies of prescription
and redemption per person aged >30-year-old were found for
ARBs combined with diuretics, and the highest frequencies were
shown for beta blocking agents (Table 3).
Proportion of ACE inhibitor (with and without diuretics)
prescription and redemption was the highest (about one third
of the total) in each deprivation group (tertiles I-III.), while the
prescription and redemption of beta blocking agents was the
second highest, and the prescription and redemption of calcium
FIGURE 3 | Relationship between the deprivation and the relative prevalence of chronic ischaemic heart diseases (A), cerebrovascular diseases (B) and hypertensive
diseases (C) in 2011–2013 in Hungary.
TABLE 2 | Relative prevalence of chronic ischaemic heart diseases, cerebrovascular diseases and hypertensive disease for 35–64 age group at the district level in
Hungary in 2012 by DI tertiles.
DI tertiles Prevalence of chronic ischaemic
heart diseases
(ICD-10.: I20-I25)
Prevalence of cerebrovascular
diseases
(ICD-10.: I60-I69)
Prevalence of hypertensive
diseases
(ICD-10.: I10-I15)
Relative prevalence (95% CI) Relative prevalence (95% CI) Relative prevalence (95% CI)
I. (least deprived) 0.736 [0.733–0.739] 0.800 [0.795–0.805] 0.938 [0.936–0.940]
II. 1.073 [1.070–1.077] 1.077 [1.071–1.083] 1.033 [1.031–1.035]
III. (most deprived) 1.308 [1.303–1.313] 1.199 [1.191–1.206] 1.046 [1.044–1.049]
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TABLE 3 | Antihypertensive utilization (prescription, redemption and redemption rate) by drug types in Hungary in 2012.
Drug types Total number of
prescription
Total number of
redemption
Frequency of
prescription
Frequency of
redemption
Redemption rate
(%)
(per person aged 30+ years)
Antihypertensives (all) 41,221,460 26,732,297 6.111 3.963 64.85
Beta blocking agents 10,136,446 7,260,132 1.503 1.076 71.62
ACE inhibitors 7,306,211 5,169,763 1.083 0.766 70.76
ACE inhibitors in combination
with diuretics
6,284,235 2,919,612 0.932 0.433 46.46
Calcium channel blockers 6,228,901 4,432,300 0.923 0.657 71.16
Diuretics 5,857,905 4,073,469 0.868 0.604 69.54
ARBs 2,750,115 1,908,731 0.408 0.283 69.41
ARBs in combination with
diuretics
2,657,647 968,290 0.394 0.144 36.43
ACE, Angiotensin converting enzyme; ARB, Angiotensin receptor blocker.
channel blockers was the third highest (Figures 4A,B, Table 4).
Representation of these drugs’ prescription and redemption
increased by deprivation level; proportions of ARB prescription
in the most deprived tertile were lower (by approximately 2%)
than that in the least deprived tertile (12.05 vs. 14.14%). The same
trend was observed in case of ARB redemption (its representation
in the most deprived tertile: 10.07%; and in the least deprived
tertile: 11.55%) (Figure 3, Table 4).
The spatial distribution of deprivation and of the relative
frequencies of prescription of the selected antihypertensive
drug prescriptions (ACE inhibitors with and without diuretics,
calcium channel blockers and ARBs with and without diuretics)
are shown at the district level in Hungary in Figure 4. Areas
of the highest deprivation showed high frequencies of ACE
inhibitor (Figures 1A,C) in midwestern, northeastern, eastern
and southwestern parts of Hungary. However, in those parts
of the country, low relative frequencies of prescriptions for
ARBs were found (Figures 1A,D), while in midswestern and
northwestern part of Hungary was associated with high relative
frequency values.
The results of the risk analysis showed a linear association of
the relative frequency of prescriptions for almost every drug with
its redemption and deprivation. However, varying associations
were found regarding ARBs and ARBs in combination with
diuretics (Table 5).
Reverse J-shaped association was detected between the relative
frequency of ARB prescriptions and deprivation. In the highest
deprivation tertile, it was lower than the national average by 3%
(relative frequency: 96.77% [96.53–97.02]) (Table 5). The relative
frequency of the prescriptions and redemptions for ARBs in
combination with diuretics showed a J-shaped association with
deprivation.
The frequency of prescription for all antihypertensive drugs
in the lowest tertile (i.e., in the least deprived tertile) was 5.7273
[5.7244–5.7302], which was 7% (relative frequency: 93% [93.72–
93.82]) lower than the Hungarian average, whilst the frequency in
tertile III (i.e., in the most deprived tertile) was 6.5809 [6.5769–
6.5850], which exceeded the national average by 7% (relative
frequency: 107% [107.04–107.17]) (Table 6). Furthermore, the
frequency of redemption for all antihypertensive drugs in the
lowest tertile was 3.6038 [3.6015–3.6061], which was 10% lower
than the national average (relative frequency: 90% [90.37–
90.49]), and in the highest tertile, the frequency was 4.6047
[4.6013–4.6081], which was 15% higher (relative frequency: 15%
[114.71–114.88]) than the national average (Table 6). Similar
linear associations were found in the relative frequency for
almost every drug, except the ARBs in combination with diuretics
prescription.
When the number of redeemed prescriptions and that of
the prescriptions for antihypertensive drugs were compared,
the redemption rate was found to be higher as the deprivation
became more pronounced, i.e., better compliance was observed
in tertile II than in tertile I, and the highest rates (independent
from the types of drugs) were always associated with the districts
with the highest deprivation (Table 7).
DISCUSSION
Inequalities in mortality and morbidity between populations
with different (lower and higher) socioeconomic positions are
widely described in the literature with a special focus on
different regions of Europe (see reviewed in Mackenbach et al.,
2017). de Gelder et al. have analyzed trends in socioeconomic
inequalities in mortality over four decades in six European
countries among them Hungary and provided a first analysis of
long-term trends in inequalities in mortality in Central/Eastern
Europe (de Gelder et al., 2017) where history had a profound
impact on mortality and life expectancy (Mackenbach, 2013).
They showed that relative inequalities in all-cause mortality
generally increased, but more so in Hungary and Norway than
elsewhere and absolute inequalities often narrowed but went
up in these two countries. In general, Central and Eastern
European countries are in which inequalities in mortality have
“disastrously exploded” since the early 1990s (Mackenbach,
2017).
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FIGURE 4 | Antihypertensive drug prescription (A) and redemption (B) by Deprivation Index tertiles and drug types in Hungary in 2012.
The East-West life expectancy gap in Europe has been a well-
known epidemiological phenomenon for a long time (Jakovljevic
et al., 2016a). It was clearly demonstrated that the difference of
extraordinary magnitude is most strongly related to the high rate
of premature mortality from cardiovascular causes (Hertzman
and Bobak, 1996). The question whether premature mortality
is the current Iron Curtain in Europe (Zatonski et al., 2016)
seems to be reasonable. The inequalities in CVD mortality and
that in preventive medication targeting CVD risk factors are very
intensely studied in the populations of the high-income EU15
countries (Alsabbagh et al., 2014; Leng et al., 2015), but reports
for the EU13 countries, especially for the most affected Central,
Eastern and Southeastern European (CESEE) EU member states,
are extremely scarce (Jakovljevic et al., 2015), and most of them
are methodologically inappropriate.
Regarding the relationship between SES and CVDs from
CESEE countries, only our group published a methodological
report on the development of a deprivation index (DI) to
characterize SES with a multidimensional composite indicator,
in which not only information about socioeconomic deprivation
in Hungary was provided but also a statistically significant
association between SES characterized by DI and the spatial
distribution of premature mortality due to diseases of the
circulatory system for the years 1998–2004 was also shown
(Juhász et al., 2010). The analysis was carried out to demonstrate
using the example of cardiovascular diseases that inequalities
in socioeconomic status may reflect the spatial distribution of
health status in a population. Our findings on the distribution of
deprivation and CVD mortality and morbidity corroborate this
hypothesis.
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TABLE 4 | Antihypertensive drug utilization by types of drugs and DI tertiles in Hungary in 2012.
DI tertiles
I. (Least deprived) II. III. (Most deprived)
Drug types Prescription
Totals (number) and proportions in percentage (%) [95% CI]
ACE inhibitors* 4,818,107 5,388,432 3,383,907
32.27 [32.24–32.29] 33.37 [33.35–33.4] 33.36 [33.33–33.39]
Beta blocking agents 3,650,127 3,963,420 2,522,899
24.45 [24.42–24.47] 24.55 [24.53–24.57] 24.87 [24.85–24.9]
Calcium channel blockers 2,199,870 2,457,276 1,571,755
14.73 [14.71–14.75] 15.22 [15.20–15.24] 15.5 [15.47–15.52]
Diuretics 2,152,211 2,263,549 1,442,145
14.41 [14.40–14.43] 14.02 [14.00–14.04] 14.22 [14.20–14.24]
ARBs** 2,111,313 2,073,681 1,222,768
14.14 [14.12–14.16] 12.84 [12.83–12.86] 12.05 [12.03–12.07]
Redemption
Totals (number) and proportions in percentage [95% CI]
ACE inhibitors* 2,757,054 3,163,058 2,169,263
29.61 [29.58–29.64] 30.54 [30.51–30.57] 30.70 [30.67–30.73]
Beta blocking agents 2,519,785 2,803,597 1,936,750
27.06 [27.04–27.09] 27.07 [27.04–27.10] 27.41 [27.38–27.44]
Calcium channel blockers 1,497,488 1,730,739 1,204,073
16.08 [16.06–16.11] 16.71 [16.69–16.73] 17.04 [17.01–17.07]
Diuretics 1,460,810 1,568,174 1,044,485
15.69 [15.67–15.71] 15.14 [15.12–15.16] 14.78 [14.76–14.81]
ARBs** 1,075,182 1,090,599 711,240
11.55 [11.53–11.57] 10.53 [10.51–10.55] 10.07 [10.04–10.09]
*, including ACE inhibitors in combination with diuretics; **, including ARBs in combination with diuretics; ACE, Angiotensin converting enzyme; ARB, Angiotensin receptor blocker.
Concerning the relationship between SES and preventive
medication to reduce CVD risk, our recent publication on
the association between statin utilization and socioeconomic
deprivation in Hungary (Boruzs et al., 2016) is the only
publication from CESEE countries. In this country-wide analysis,
the standardized premature CVD mortality rates, frequency of
statin prescriptions, redeemed statin prescriptions, and ratios
for compliance compared to the national average were mapped,
and their associations with deprivation (tertile of deprivation
index as a district-based categorical covariate) were defined. The
risk analysis showed a significant positive association between
deprivation and the relative risk of premature cardiovascular
mortality and a reverse J-shaped association between the relative
frequency of statin prescriptions and deprivation. Districts
with the highest deprivation showed a low relative frequency
of statin prescriptions; however, significantly higher primary
compliance (redemption) was observed in these districts. Our
data clearly suggest that insufficient statin utilization may
represent a significant barrier to reducing CVD mortality,
particularly among people living in highly deprived areas of the
country. Nevertheless, it is worth mentioning that in Hungary
the high prevalence of health behavior risk factors (as smoking,
uncontrolled alcohol consumption, physical inactivity, unhealthy
nutrition, etc.) is a severe problem regarding the prevention
of chronic diseases (Sándor et al., 2017). Among Roma heavy
smoking and unhealthy diet were 1.5–3 times more prevalent
than in the general Hungarian population (Kósa et al., 2007;
Sándor et al., 2017). The lower prevalence of healthy lifestyle
activities among lower educated, lower income and elder people
living in highly deprived small settlements was observed (Paulik
et al., 2010, 2011). Several policies (anti-smoking legislation, new
taxes on “unhealthy” food as sweetened, salty and fatty products)
were introduced by the Hungarian government to facilitate
favorable changes in health behaviors, but in all probability
quadrupling of public works expenditure in the period between
2010 and 2015 had the most profound effect (Sándor et al., 2017).
In the period between 2009 and 2013 the unemployment rate
in Hungary was above 10%, which—by introducing the public
work program—fell to 6.6% in 2015 (World Health Organization.
European health information gateway, 2017).
Our present study was designed to investigate the field
of antihypertensive utilization and its association with the
socioeconomic characteristics of various population groups in
Hungary by focusing on the comparative analysis of data
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TABLE 5 | Relative frequency of the prescription and redemption of antihypertensive drugs at the district level in Hungary in 2012 by DI tertiles.
DI tertiles
I. (Least deprived) II. III. (Most deprived)
Prescription
Drug types Relative frequency [95% CI]
Antihypertensives (all) 0.9377 [0.9372–0.9382] 1.0201 [1.0196–1.0206] 1.0711 [1.0704–1.0717]
Beta blocking agents 0.9338 [0.9329–0.9348] 1.0166 [1.0156–1.0176] 1.0833 [1.0819–1.0846]
ACE inhibitors 0.9253 [0.9240–0.9260] 1.0386 [1.0370–1.0400] 1.0610 [1.0590–1.0630]
ACE inhibitors in combination with diuretics 0.9139 [0.9127–0.9151] 1.0222 [1.0210–1.0235] 1.1064 [1.1047–1.1081]
Calcium channel blockers 0.9168 [0.9155–0.9180] 1.0257 [1.0245–1.0270] 1.0963 [1.0946–1.0980]
Diuretics 0.9481 [0.9469–0.9494] 1.0088 [1.0075–1.0102] 1.0728 [1.0711–1.0746]
ARBs 0.9988 [0.9969–1.0007] 1.0205 [1.0186–1.0224] 0.9677 [0.9653–0.9702]
ARBs in combination with diuretics 1.0040 [1.0021–1.0059] 0.9889 [0.9870–0.9909] 1.0116 [1.0091–1.0142]
Redemption
Relative frequency [95% CI]
Antihypertensives (all) 0.9043 [0.9037–0.9049] 1.0073 [1.0066–1.0079] 1.1480 [1.1471–1.1488]
Beta blocking agents 0.9029 [0.9018–0.9040] 1.0020 [1.0009–1.0032] 1.1588 [1.1572–1.1604]
ACE inhibitors 0.8885 [0.8872–0.8898] 1.0259 [1.0245–1.0273] 1.1429 [1.1410–1.1448]
ACE inhibitors in combination with diuretics 0.8810 [0.8793–0.8828] 0.9991 [0.9973–1.0009] 1.2000 [1.1974–1.2027]
Calcium channel blockers 0.8799 [0.8785–0.8813] 1.0133 [1.0118–1.0148] 1.1776 [1.1755–1.1797]
Diuretics 0.9263 [0.9248–0.9278] 1.0047 [1.0031–1.0063] 1.1165 [1.1143–1.1186]
ARBs 0.9656 [0.9633–0.9678] 1.0089 [1.0066–1.0112] 1.0430 [1.0400–1.0460]
ARBs in combination with diuretics 0.9656 [0.9625–0.9687] 0.9508 [0.9476–0.9539] 1.1399 [1.1355–1.1443]
ACE, Angiotensin converting enzyme; ARB, Angiotensin receptor blocker.
for prescriptions by general practitioners and the redeemed
prescriptions for antihypertensive drugs at the district level
during 2012. In addition, investigations on the relationship
between deprivation and premature mortality caused by different
CVDs (among them hypertension) as well as between deprivation
and their prevalence were also carried out.
To the best of our knowledge, this is the first comprehensive
study that analyzed the relationship of SES with CVD mortality,
morbidity, and the utilization of antihypertensive drugs in a
CESEE country characterized by an extremely high relative risk of
premature CVD mortality using a multidimensional composite
indicator to properly characterize the SES and using risk analysis
capabilities to estimate the relationships between deprivation
and CVD burden as well as antihypertensive medication. In
complexity, this study is unique among the previously published
studies in this field from different countries around the world.
Risk analysis showed a significant association of the risk of
premature cardiovascular and cerebrovascular mortality with
deprivation. The spatial pattern of prevalence values for different
diseases was similar to the distribution of their relative risk of
mortality; however, inequality was less dramatic for hypertensive
diseases. Based on the fact that the prevalence of hypertension
exceeded the national average by only 4% in the areas of
the highest deprivation tertile, while the prevalence of chronic
ischaemic heart diseases and cerebrovascular diseases was higher
than the national average by approximately 30% and 20%,
respectively, it is reasonable to suppose that in a significant
number of cases, hypertension remains unknown until the
manifestation of its complications, i.e., late diagnosis. This
assumption is supported by the findings that the frequency
of prescriptions for all antihypertensive drugs is 7% higher
than the national average, while the frequency of redemption
is 15% higher than the national average in the regions with
the highest deprivation. The higher frequency of prescriptions
may indicate that fewer hypertensive patients can be controlled
on monotherapy, i.e., more patients require more than one
anti-hypertensive medication for blood pressure control, while
the significantly lower level of primary non-compliance may
indicate that the patients take medical advice when symptoms of
hypertensive crisis appear or in comorbid conditions.
The patterns of antihypertensive drugs prescription and
redemption significantly differ by DI tertile; although the
differences expressed in a percentage seem to be small,
they are statistically significant due to the large number of
observations. In areas of the highest deprivation, higher relative
frequencies of ACE inhibitor, beta blocker and calcium channel
blocker prescriptions and lower relative frequency of ARB
prescriptions were found. The representation of ARBs among
the antihypertensive medications used was increased with the
improvement of socioeconomic status. These findings concur
with the observation of a registry-based study on the types
of antihypertensive medications used in ambulatory settings in
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TABLE 6 | Frequency of the prescription and redemption of antihypertensive drugs per person aged 30+ years, at the district level in Hungary in 2012 by DI tertile.
DI tertiles
I. (least deprived) II. III. (most deprived)
Prescription
Drug types Frequency per person aged 30+ years [95% CI]
Antihypertensives (all) 5.7273 [5.7244–5.7302] 6.2766 [6.2735–6.2796] 6.5809 [6.5769–6.5850]
Beta blocking agents 1.4062 [1.4048–1.4077] 1.5408 [1.5392–1.5423] 1.6320 [1.6300–1.6340]
ACE inhibitors 1.0050 [1.0037–1.0062] 1.1341 [1.1328–1.1354] 1.1673 [1.1656–1.1691]
ACE inhibitors in combination with diuretics 0.8535 [0.8531–0.8539] 0.9606 [0.9604–0.9609] 1.0417 [1.0401–1.0433]
Calcium channel blockers 0.8428 [0.8423–0.8432] 0.9529 [0.9527–0.9532] 1.0161 [1.0146–1.0177]
Diuretics 0.8215 [0.8210–0.8220] 0.8768 [0.8764–0.8772] 0.9305 [0.9301–0.9309]
ARBs 0.4067 [0.4061–0.4073] 0.4163 [0.4157–0.4169] 0.3951 [0.3943–0.3959]
ARBs in combination with diuretics 0.3992 [0.3986–0.3998] 0.3869 [0.3863–0.3875] 0.3980 [0.3972–0.3988]
Redemption
Frequency per person aged 30+ years [95% CI]
Antihypertensives (all) 3.6038 [3.6015–3.6061] 4.0398 [4.0373–4.0422] 4.6047 [4.6013–4.6081]
Beta blocking agents 0.9802 [0.9790–0.9814] 1.0926 [1.0913–1.0938] 1.2585 [1.2568–1.2603]
ACE inhibitors 0.6869 [0.6864–0.6875] 0.7972 [0.7967–0.7977] 0.8949 [0.8945–0.8954]
ACE inhibitors in combination with diuretics 0.3776 [0.3771–0.3782] 0.4348 [0.4342–0.4354] 0.5291 [0.5283–0.5299]
Calcium channel blockers 0.5716 [0.5710–0.5722] 0.6704 [0.6698–0.6710] 0.7817 [0.7810–0.7823]
Diuretics 0.5576 [0.5570–0.5582] 0.6074 [0.6068–0.6080] 0.6764 [0.6757–0.6772]
ARBs 0.2719 [0.2713–0.2724] 0.2856 [0.2851–0.2862] 0.2982 [0.2974–0.2989]
ARBs in combination with diuretics 0.1390 [0.1386–0.1394] 0.1373 [0.1369–0.1377] 0.1656 [0.1651–0.1663]
ACE, Angiotensin converting enzyme; ARB, Angiotensin receptor blocker.
TABLE 7 | Redemption rate of antihypertensive drugs by DI tertiles at the district level in Hungary in 2012.
DI tertiles
I. (Least deprived) II. III. (Most deprived)
Drug types Redemption rate (%) [95% CI]
Antihypertensives (all) 62.35 [62.33–62.38] 64.14 [64.12–64.16] 69.66 [69.63–69.69]
Beta blocking agents 69.39 [69.33–69.44] 70.84 [70.79–70.88] 76.27 [76.21–76.33]
ACE inhibitors 68.11 [68.05–68.18] 70.10 [70.04–70.15] 75.77 [75.70–75.84]
ACE inhibitors in combination with diuretics 44.84 [44.77–44.90] 45.34 [45.28–45.40] 50.42 [50.34–50.49]
Calcium channel blockers 68.07 [68.01–68.13] 70.43 [70.38–70.49] 76.61 [76.54–76.67]
Diuretics 67.87 [67.81–67.94] 69.28 [69.22–69.34] 72.43 [72.35–72.50]
ARBs 67.17 [67.07–67.27] 68.97 [68.88–69.06] 74.71 [74.58–74.83]
ARBs in combination with diuretics 35.04 [34.94–35.14] 35.29 [35.20–35.39] 41.20 [41.06–41.34]
ACE, Angiotensin converting enzyme; ARB, Angiotensin receptor blocker.
Finland (Härkönen et al., 2015) that high income patients were
more likely to use ARBs, while low income patients were more
likely to use beta blockers and ACE inhibitors.
Concerning the history of hypertension treatment (Saklayen
and Deshpande, 2016) from the discovery of blood pressure
lowering effect of thiazides and thiazide-like compounds (Freis
et al., 1958) more and more potential pharmacological targets
became known and these findings lead to the development
and introduction of novel antihypertensive medicines. The
milestones on this process are the multicentre randomized
placebo-controlled clinical trials—from VA (1967) through
TOMHS (1993); ALLHAT (2002) and ASCOT (2005)—among
others—to SPRINT (2015) - which were designed not only
to clinically test some newly discovered drugs, but also to
characterize and compare their effects on CVD morbidity
and mortality. The recently completed SPRINT study showed
huge reduction in mortality (25%) and CVD events (30%) in
the group with systolic blood pressure goal of 120 mmHg
(SPRINTResearch Group, 2015). Large randomized clinical trials
have provided strong evidence that antihypertensive treatment
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substantially reduces the risk of overall mortality, especially that
of cardiovascular diseases as stroke and coronary heart diseases
(Chobanian et al., 2003; Turnbull et al., 2008). On the basis of
results obtained in meta-analysis of data published on the effect
of antihypertensive treatment on secondary prevention of CVD
events and all-cause mortality among persons without clinically
defined hypertension it could be concluded that even among
patients with clinical history of CVD but without hypertension,
antihypertensive treatment is associated with decreased risk of
stroke, congestive heart failure, composite CVD events, and
all-cause mortality (Thompson et al., 2011).
Different types of antihypertensive drugs show different
effectiveness for the treatment of hypertension. When
perindopril as a new ACE inhibitor drug was introduced
among patients with stable coronary heart disease it was
showed in the EUROPA study that perindopril treatment
can significantly improve outcome, namely it results in a
20% additional risk reduction (Fox and EURopean trial
On reduction of cardiac events with Perindopril in stable
coronary Artery disease Investigators, 2003). The study
group concluded that “treatment with perindopril, on top
of other preventive medications, should be considered
in all patients with coronary heart disease.” Angiotensin
II receptor blockers (ARBs) as “recent advances in risk
reduction” were interpreted on the basis of results obtained
in the ONTARGET trial (Guthrie, 2009) in which the ACE
inhibitor ramipril and the ARB telmisartan were found equally
effective in reducing the incidence of cardiovascular death,
myocardial infarction, stroke, and hospitalization for heart
failure in patients at high risk for cardiovascular disease. In
spite of new and new drug discoveries a large scale study
designed to compare the effectiveness of thiazide diuretic
(TD), ACE inhibitors, ARBs and calcium channel blocker
(CCB) monotherapies for the treatment of hypertension on
565,009 patients the authors found that patients who took
TDs experienced a lower risk of clinical events compared with
patients who took ACE inhibitors, ARBs and CCBs. These
results provide a strong rationale for choosing TDs as first-line
monotherapy for the control of hypertension (Machado et al.,
2017).
In a carefully designed meta-analysis of publications on the
relationship between SES and hypertension, Leng et al. could
identify only a single publication from the CESEE countries,
and even this report lacked considerable merit (Leng et al.,
2015). This single study was carried out among central Slovakian
adults with a small sample size of 100 probands (50 males
and 50 females) in which only 14 participants with low SES
were identified; among them, hypertension was found to be less
frequent than in the group of participants with high SES (n= 15).
Concerning the sample size, this finding could not be considered
substantial even if the authors themselves did not report, in the
very same paper, a conflicting result; namely, when the group
was stratified by educational level, the prevalence of hypertension
was found to be highest in the least educated group (Hujova
and Rostakova, 2013). Studies on Roma, the most disadvantaged
ethnic population of the European Union that is accumulating
in the CESEE countries, did not reveal significant differences
by ethnicity regarding hypertension between Roma and the
host populations (Vozarova de Courten et al., 2003; Babinska
et al., 2013; Kósa et al., 2015) in Slovakia and Hungary, but the
prevalence of hypertension in the Bayash Roma population was
significantly lower than what is usually reported for the general
population of Croatia (Zeljko et al., 2008). Only a single report
mentions a higher prevalence of hypertension among Slovakian
Roma than in the general population (Dolinska et al., 2007).
There are some limitations that need to be considered in
the interpretation of our findings. In our ecological study the
associations detected by the investigation do not prove a causal
relationship. The deprivation associated with mortality and
preventive medication at the population level may not necessarily
be associated with mortality and preventive medication in
individuals (Morgenstern, 1995). All of the factors (related
to patients, physicians, and health system) that have an
effect on antihypertensive utilization cannot be covered in
a single study. The effects associated with socioeconomic
factors may be mediated by other factors that were not
included in our analyses (Radevic et al., 2016). Health system
factors were only partially studied, and access to care requires
particular attention in future studies (Jakovljevic et al., 2016b).
Information about various elements that may influence a patient’s
likelihood to take antihypertensive medications should also be
collected to understand the very low relative redemption rate
in case of ARBs and ACE inhibitors when combined with
diuretics.
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